Massachusetts Financial Services Co. MA Has $21.31 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Massachusetts Financial Services Co. MA increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 18.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 713,854 shares of the specialty pharmaceutical company's stock after acquiring an additional 109,655 shares during the period. Massachusetts Financial Services Co. MA owned approximately 2.22% of Collegium Pharmaceutical worth $21,309,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Invesco Ltd. boosted its position in shares of Collegium Pharmaceutical by 19.5% during the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after purchasing an additional 289,335 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Collegium Pharmaceutical by 319.4% in the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after buying an additional 221,903 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth about $3,489,000. Raymond James Financial Inc. acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth about $2,432,000. Finally, F M Investments LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth about $2,096,000.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of Collegium Pharmaceutical stock in a transaction on Monday, June 9th. The shares were sold at an average price of $30.62, for a total transaction of $202,122.62. Following the sale, the director owned 70,658 shares in the company, valued at $2,163,547.96. The trade was a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded down $1.06 during trading on Friday, reaching $31.20. The stock had a trading volume of 219,382 shares, compared to its average volume of 397,390. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of 25.57 and a beta of 0.64. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The stock has a fifty day simple moving average of $30.14 and a two-hundred day simple moving average of $29.71.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The company's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.45 EPS. As a group, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical announced that its Board of Directors has approved a stock buyback plan on Monday, July 7th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the specialty pharmaceutical company to buy up to 15.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts have commented on COLL shares. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Piper Sandler reiterated a "neutral" rating and issued a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Finally, Wall Street Zen lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.75.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.